SEC Form 4 · accession 0000899243-19-002330
XERIS PHARMACEUTICALS INC · XERS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul R Edick
Officer — See Remarks · Director
Period of report
Jan 31, 2019
Accepted (ET)
Feb 1, 2019 · 4:42 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001346302
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 31, 2019 | A | 125,000 | $0.00 | A | 125,000 | D | |
| Common StockF2 | holding | — | — | — | 13,430 | I | By: Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018 |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $13.88 | Jan 31, 2019 | A | 200,000 | A | — | Jan 31, 2029 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. 25% of these restricted stock units shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months.
- F2The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- F325% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months.
Remarks
Chairman, President & Chief Executive Officer